Photo credits: INCATE

Cavenagh Health exists to foster innovation and support the creation of new life sciences companies that address some of the most urgent global health challenges of our time. Antimicrobial resistance (AMR) is undeniably one of those. As a testament to this commitment, we are delighted to partner with INCATE to further our part in the fight against the growing threat of AMR.

Our shared vision extends beyond talent—it’s about building the teams, expertise, and resources that drive meaningful change. By fostering collaboration across industry experts, entrepreneurs, and investors, we will help push the boundaries of innovation and bring the right people to support the acceleration of the development of new therapies, diagnostics, and interventions that will significantly reduce the prevalence and impact of this pressing issue.

So far this year we have already joined forces with INCATE on a number of initiatives. In February, we co-published the whitepaper “Beyond Antibiotics: The Reckoning of Antimicrobial Resistance – A New Biological Frontier,” issuing a clear call to action for the industry, urging immediate attention, innovation, and sustainable approaches to combat AMR.

At the 8th AMR Conference in March, we had the privilege of joining INCATE to host the workshop “Phages: What’s New and What’s Next?” Our Principal, Guillermo Tramontin, shared his perspectives and insights into the sector’s challenges and the potential of phage therapies as a transformative solution to AMR.

During this year’s Swiss Biotech Day, we ensured that AMR was centre stage, hosting and moderating a panel discussion with Menarini Group. Building on our whitepaper’s success, this discussion explored the intersection of oncology and infectious diseases, the need for scalable manufacturing pathways, talent acquisition strategies, and Switzerland’s pivotal role in antibiotic development.

As we formalise our partnership, this next step represents the natural evolution of our shared commitment to keep pushing this critical agenda forward. As part of this, we will be dedicating expertise to supporting INCATE’s portfolio companies, providing advice, access to funding, and leveraging their extensive industry networks. Already playing a valuable role in accelerating early-stage innovations in AMR, our sustained involvement will ensure that startups survive and thrive, equipping them with the resources and guidance needed to make a lasting impact on global health.

This official step marks the next phase of our journey together, further fuelling the shared vision for a bright future for AMR as we continue to bring valuable opportunities to the industry and our community. We’re looking forward to being able to share the details of new initiatives and witnessing the impact of innovation and collaboration that we know will deliver tangible results as we all collectively remain committed to confronting the global threat of AMR and shaping a healthier future for all.

A post by Cavenagh Health